<DOC>
	<DOCNO>NCT01594827</DOCNO>
	<brief_summary>The prevalence methicillin resistant Staphylococcus aureus ( MRSA ) respiratory infection Cystic Fibrosis ( CF ) increase dramatically last decade . Evidence suggest persistent infection MRSA may result increased rate decline FEV1 shorten survival . Currently conclusive study demonstrate effective aggressive treatment protocol persistent MRSA respiratory infection CF . Data demonstrate effective safe method clear persistent MRSA infection need . The purpose study evaluate safety efficacy 28-day course vancomycin inhalation , 250 mg twice day , ( combination oral antibiotic ) eliminate MRSA respiratory tract individual CF persistent MRSA infection . Subjects assign 1:1 ratio either vancomycin inhalation ( 250 mg twice day ) taste match placebo follow 3 additional month . In addition , group receive oral rifampin , second oral antibiotic ( TMP-SMX doxycycline , protocol determine ) , mupirocin intranasal cream chlorhexidine body wash . Forty patient persistent respiratory tract MRSA infection enrol trial .</brief_summary>
	<brief_title>Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol ( PMEP )</brief_title>
	<detailed_description>Primary Objectives The primary objective trial : 1 . Determine efficacy aggressive treatment protocol eradicate persistent MRSA infection individual CF . 2 . Determine safety aggressive treatment protocol eradicate persistent MRSA infection individual CF . Secondary Objectives The secondary objective trial : 1 . Determine efficacy aggressive treatment protocol improve FEV1 , time exacerbation , quality life individual CF persistent MRSA infection . 2 . Determine benefit add nebulized vancomycin aggressive oral antibiotic treatment protocol eradicate persistent MRSA infection individual CF .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Mupirocin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>1 . Male female ≥ 12 year age . 2 . Confirmed diagnosis CF base follow criterion : positive sweat chloride &gt; 60 mEq/liter ( pilocarpine iontophoresis ) and/or genotype two identifiable mutation consistent CF abnormal NPD , one clinical feature consistent CF phenotype . 3 . Written informed consent ( assent applicable ) obtain subject subject 's legal representative ability subject comply requirement study . 4 . Two positive MRSA respiratory culture last two year least six month apart , plus positive MRSA respiratory culture Screening Visit Runin ( Day 14 ) Visit . 5 . At least 50 % respiratory culture time first MRSA culture ( last two year ) positive MRSA . 6 . FEV1 &gt; 40 % predict normal age , gender , height Screening , subject 18 year age older.. 7 . FEV1 &gt; 60 % predict normal age , gender , height Screening , subject 1217 year old . 8 . Females childbearing potential must agree practice one highly effective method birth control , include abstinence . Note : highly effective method birth control , alone combination , result failure rate le 1 % per year use consistently correctly . Female patient utilize hormonal contraceptive birth control method must use method least 3 month study dose . If patient use hormonal form contraception , patient require also use barrier contraceptive rifampin affect reliability hormone therapy . Barrier contraceptives male condom diaphragm acceptable use combination spermicides 1 . An acute upper low respiratory infection , pulmonary exacerbation , change routine therapy ( include antibiotic ) pulmonary disease within 42 day Day 1 Visit ( 2 week prior Screening visit ) . 2 . Individuals chronic continuous inhale antibiotic without interruption willing substitute vancomycin placebo schedule inhaled antibiotic day 028 study ( every month inhale antibiotic acceptable ) 3 . Use oral inhale antiMRSA drug within two week Screening Visit . 4 . History intolerance inhale vancomycin inhale albuterol . 5 . History intolerance rifampin TMP/SMX doxycycline . 6 . Resistance rifampin TMP/SMX doxycycline Screening . 7 . Resistance vancomycin Screening . 8 . Abnormal renal function , define creatinine clearance &lt; 50 mL/min use CockcroftGault equation adult Schwartz equation child , Screening . 9 . Abnormal liver function , define ≥ 3x upper limit normal ( ULN ) , serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) , know cirrhosis . time Screening . 10 . Serum hematology chemistry result judgment investigator would interfere completion study . 11 . History list solid organ hematological transplantation 12 . History sputum culture nontuberculous Mycobacteria last 6 month . 13 . History sputum culture Burkholderia Cepacia last year . 14 . Planned continuous use soft contact lenses take rifampin access glass . 15 . Current use oral corticosteroid dos exceed equivalent 10 mg prednisone day 20 mg prednisone every day 16 . Administration investigational drug device within 28 day Screening within 6 halflives investigational drug ( whichever longer ) . 17 . Patients inhaled antibiotic must regimen 4 month prior screen 18 . Female patient childbearing potential pregnant lactating , plan become pregnant 19 . Any serious active medical psychiatric illness , opinion investigator , would interfere patient treatment , assessment , adherence protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Methicillin-resistant Staphylococcus aureus</keyword>
	<keyword>Vancomycin</keyword>
</DOC>